[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fK6J9m6yiebSLVeoqUDjMKebx2kUPqqh8X3s8dY2x4iA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":44,"rows":51},"IRCCS Eugenio Medea",[4],105,false,40,1,7324,2,98,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Cerebral Palsy",13,{"name":18,"count":19},"Acquired Brain Injury",10,{"name":21,"count":22},"Autism Spectrum Disorder",8,{"name":24,"count":25},"Muscular Dystrophies",4,{"name":27,"count":25},"Epilepsy",{"name":29,"count":25},"Parent-Child Relations",{"name":31,"count":25},"Neurodevelopmental Disorder (Diagnosis)",{"name":33,"count":25},"Developmental Dyslexia",[35,40],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06851377","Expanding NGS Data with Optical Genome Mapping (OGM)","2026-12","Optical Genome Mapping",{"nctId":41,"briefTitle":42,"date":38,"intervention":43},"NCT07273695","Assessing Real Life Effectiveness of Treatment in Neurodevelopmental Disorders","methyphenidate",[45,46,47,48,49,50],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[52,84,110,135,161,185],{"intervention":39,"totalTrials":11,"cells":53},{"EARLY_PHASE1":54,"PHASE1":57,"PHASE2":59,"PHASE3":61,"PHASE4":63,"NA":65},{"trials":55,"activeCount":56},[],0,{"trials":58,"activeCount":56},[],{"trials":60,"activeCount":56},[],{"trials":62,"activeCount":56},[],{"trials":64,"activeCount":56},[],{"trials":66,"activeCount":9,"soonestReadout":38},[67,77],{"nctId":68,"briefTitle":69,"status":70,"phases":71,"primaryCompletion":72,"completion":72,"start":73,"enrollment":74,"conditions":75,"interventions":76},"NCT06347562","Optical Genome Mapping for the Diagnosis of Neurodevelopmental Disorders","UNKNOWN",[50],"2025-06-14","2022-06-15",58,[31],[39],{"nctId":36,"briefTitle":37,"status":78,"phases":79,"primaryCompletion":38,"completion":38,"start":80,"enrollment":81,"conditions":82,"interventions":83},"RECRUITING",[50],"2024-05-23",60,[31],[39],{"intervention":43,"totalTrials":9,"cells":85},{"EARLY_PHASE1":86,"PHASE1":88,"PHASE2":90,"PHASE3":92,"PHASE4":94,"NA":96},{"trials":87,"activeCount":56},[],{"trials":89,"activeCount":56},[],{"trials":91,"activeCount":56},[],{"trials":93,"activeCount":56},[],{"trials":95,"activeCount":56},[],{"trials":97,"activeCount":9,"soonestReadout":38},[98],{"nctId":41,"briefTitle":42,"status":78,"phases":99,"primaryCompletion":38,"completion":38,"start":100,"enrollment":101,"conditions":102,"interventions":109},[],"2025-09-19",80,[103,104,105,106,107,108],"Emotional Dysregulation","Externalizing Problems","Oppositional Defiant","Conduct Disorder","Disruptive Behaviours","Attention Deficit Hyerpactivity Disorder",[43],{"intervention":111,"totalTrials":9,"cells":112},"Methylphenidate",{"EARLY_PHASE1":113,"PHASE1":115,"PHASE2":117,"PHASE3":119,"PHASE4":121,"NA":133},{"trials":114,"activeCount":56},[],{"trials":116,"activeCount":56},[],{"trials":118,"activeCount":56},[],{"trials":120,"activeCount":56},[],{"trials":122,"activeCount":56},[123],{"nctId":124,"briefTitle":125,"status":70,"phases":126,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":132},"NCT04272021","Multi Neuro-functional Biomarkers for Monitoring the Effects of Treatments in ADHD Children",[49],"2023-12","2018-04-13",20,[131],"Attention Deficit Hyperactivity Disorder",[111],{"trials":134,"activeCount":56},[],{"intervention":136,"totalTrials":9,"cells":137},"Etravirine",{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":155,"PHASE4":157,"NA":159},{"trials":139,"activeCount":56},[],{"trials":141,"activeCount":56},[],{"trials":143,"activeCount":56},[144],{"nctId":145,"briefTitle":146,"status":147,"phases":148,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":152,"interventions":154},"NCT04273165","Safety and Efficacy of Etravirine in Friedreich Ataxia Patients","COMPLETED",[47],"2023-01-17","2020-09-17",30,[153],"Friedreich Ataxia",[136],{"trials":156,"activeCount":56},[],{"trials":158,"activeCount":56},[],{"trials":160,"activeCount":56},[],{"intervention":162,"totalTrials":9,"cells":163},"gamma interferon",{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":179,"PHASE4":181,"NA":183},{"trials":165,"activeCount":56},[],{"trials":167,"activeCount":56},[],{"trials":169,"activeCount":56},[170],{"nctId":171,"briefTitle":172,"status":147,"phases":173,"primaryCompletion":174,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":178},"NCT03888664","Open Trail of γIFN for Friedreich Ataxia",[47],"2017-12-31","2016-06-26",12,[153],[162],{"trials":180,"activeCount":56},[],{"trials":182,"activeCount":56},[],{"trials":184,"activeCount":56},[],{"intervention":186,"totalTrials":9,"cells":187},"DNA methylation of target genes",{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":194,"PHASE4":196,"NA":198},{"trials":189,"activeCount":56},[],{"trials":191,"activeCount":56},[],{"trials":193,"activeCount":56},[],{"trials":195,"activeCount":56},[],{"trials":197,"activeCount":56},[],{"trials":199,"activeCount":56},[200],{"nctId":201,"briefTitle":202,"status":70,"phases":203,"primaryCompletion":204,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":211},"NCT04804280","Epigenetics and Protective Factors in the Preterm Infant",[],"2024-04-04","2024-09-04","2019-01-01",94,[209,29,210],"Preterm Birth","Epigenetics",[186]]